News

The J&J scientists said that out of 75,000 participants in a clinical trial, there was just one case of cerebral venous sinus thrombosis.

While none are officially FDA approved, the agency has cleared them under emergency use authorization.

Round 2 is a $249.95 million federal initiative that builds on the $200 million program established as part of the CARES Act.

The impact of COVID-19 is felt most severely in communities of color, yet the disparities have not been the result of the pandemic.

The signees view the lack of a second application period as a hindrance to the move toward value-based care.

Revenues, profit and earnings per share all saw increases both month-over-month and year-over-year.

Average seller size by revenue was $676 million, well above historical averages for the first quarter and for recent year-end averages.

Even with temporary hold on third vaccine, there is enough of a supply of Moderna and Pfizer to vaccinate every American, Biden says.

Anumana will develop and market algorithms for early detection of disease. Lucem Health can collect device data and feed it into clinical workflows. Both spin-offs aim to capitalize on advances in AI and remote telemetry.

Vaccine opposition at a social media event inspired the creation of new guidelines to combat misinformation.